top of page

Modality profile: Bi-Specifics and cytokines at #ASCO23

blonca9
Jun 3, 2023
1 min read

Updated: Jun 15, 2023

Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.

Recent Posts

SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions

SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions

SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

SF Healthcare Week: Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment, Deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead

SF Healthcare Week: Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment, Deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page